CNS Drugs

[vc_row][vc_column width=”1/2″][dt_gap height=”10″][vc_column_text]

CNS Drugs

[/vc_column_text][dt_gap height=”10″][vc_column_text]Challenges of developing CNS drugs

  • Every area of drug discovery has challenges, and this is especially true for compounds that act in the brain. Our group has special expertise in discovering CNS drugs.
[/vc_column_text][dt_gap height=”10″][vc_column_text]We have the experience and proven track record to:

  • Design compounds that maintain appropriate physicochemical
    parameters (mw, PSA, lipophilicity, etc)
  • Improve CNS exposure by improving passive permeability and
    eliminating efflux transporter susceptibility
  • Proactively recognize and avoid common latent risks including hERG activity and phospholipidosis.
  • Design PET ligands and other receptor occupancy tools
[/vc_column_text][/vc_column][vc_column width=”1/2″][dt_gap height=”10″][vc_column_text][dt_cell width=”1/2″]Therapeutic expertise. We have developed and delivered candidates that reached pre-IND tox
and beyond for targets in these disease areas:


  • Alzheimer’s disease
  • Psychosis
  • Depression
  • Neuropathic pain
[/dt_cell][dt_cell width=”1/2″] skeleton1
[/dt_cell][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][dt_gap height=”30″][vc_column_text]References:
Targets and Emerging Therapies for Schizophrenia, 2012, Wiley Press. Edited by Jeffrey S. Albert and Michael W. Wood (Link)[/vc_column_text][/vc_column][/vc_row]